https://orcid.org/0000-0002-3485-6275
References
- Sawyer LM , Cornic L , Levin LÅ , Gibbons C , Møller AH , Jemec GB . Long-term efficacy of novel therapies in moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis of PASI response. J Eur Acad Dermatol Venereol . 2019;33(2):355–366. doi:10.1111/jdv.15277 30289198
- Augustin M , Krüger K , Radtke MA , Schwippl I , Reich K . Disease severity, quality of life and health care in plaque-type psoriasis: a multicenter cross-sectional study in Germany. Dermatology . 2008;216(4):366–372. doi:10.1159/000119415 18319601
- Ryan C , Kirby B . Psoriasis is a systemic disease with multiple cardiovascular and metabolic comorbidities. Dermatol Clin . 2015;33(1):41–55. doi:10.1016/j.det.2014.09.004 25412782
- Ryan C , Kirby B , Tilg H , et al. Inflammatory pathways and insulin action. Ann Rheum Dis . 2003;27(1):321–328. doi:10.1038/sj.ijo.0802502
- Wolk K , Sabat R . Adipokines in psoriasis: an important link between skin inflammation and metabolic alterations. Rev Endocr Metab Disord . 2016;17(3):305–317. doi:10.1007/s11154-016-9381-0 27554109
- Gooderham M , Papp K . Selective phosphodiesterase inhibitors for psoriasis: focus on apremilast. BioDrugs . 2015;29(5):327–339. doi:10.1007/s40259-015-0144-3 26481941
- Edwards CJ , Blanco FJ , Crowley J , et al. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a Phase III, randomised, controlled trial (PALACE 3). Ann Rheum Dis . 2016;75(6):1065–1073. doi:10.1136/annrheumdis-2015-207963 26792812
- Armstrong AW , Harskamp CT , Armstrong EJ . Psoriasis and the risk of diabetes mellitus: a systematic review and meta-analysis. JAMA Dermatol . 2013;149(1):84–91. doi:10.1001/2013.jamadermatol.406 23407990
- Coto-Segura P , Eiris-Salvado N , González-Lara L , et al. Psoriasis, psoriatic arthritis and type 2 diabetes mellitus: a systematic review and meta-analysis. Br J Dermatol . 2013;169(4):783–793. doi:10.1111/bjd.12473 23772556
- Ganzetti G , Campanati A , Liberati G , Offidani A . Metabolic features in psoriasis. Psoriasis . 2012. doi:10.5772/26129
- Houslay MD , Schafer P , Zhang KYJ . Keynote review: phosphodiesterase-4 as a therapeutic target. Drug Discov Today . 2005;10(22):1503–1519. doi:10.1016/S1359-6446(05)03622-6 16257373
- Ding H , Zhang P , Li N , Liu Y , Wang P . The phosphodiesterase type 4 inhibitor roflumilast suppresses inflammation to improve diabetic bladder dysfunction rats. Int Urol Nephrol . 2019;51(2):253–260. doi:10.1007/s11255-018-2038-z 30474782
- Muo IM , Park S-J , Smith A , et al. Compound D159687, a phosphodiesterase 4D inhibitor, induces weight and fat mass loss in aged mice without changing lean mass, physical and cognitive function. Biochem Biophys Res Commun . 2018;506(4):1059–1064. doi:10.1016/j.bbrc.2018.10.180 30409425
- Muo IM , MacDonald SD , Madan R , et al. Early effects of roflumilast on insulin sensitivity in adults with prediabetes and overweight/obesity involve age-associated fat mass loss - results of an exploratory study. Diabetes Metab Syndr Obes . 2019;12:743–759. doi:10.2147/DMSO.S182953 31213865